These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10571274)

  • 1. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs.
    Bekersky I; Boswell GW; Hiles R; Fielding RM; Buell D; Walsh TJ
    Pharm Res; 1999 Nov; 16(11):1694-701. PubMed ID: 10571274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats.
    Bekersky I; Boswell GW; Hiles R; Fielding RM; Buell D; Walsh TJ
    Pharm Res; 2000 Dec; 17(12):1494-502. PubMed ID: 11303959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
    Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
    Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers.
    Bekersky I; Fielding RM; Dressler DE; Kline S; Buell DN; Walsh TJ
    J Clin Pharmacol; 2001 Sep; 41(9):963-71. PubMed ID: 11549101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
    Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
    Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of conventional and lipid emulsion formulations of amphotericin B: Pharmacokinetics and toxicokinetics in dogs.
    Nieto J; Alvar J; Rodríguez C; San Andrés MI; San Andrés MD; González F
    Res Vet Sci; 2018 Apr; 117():125-132. PubMed ID: 29272720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition.
    Kagan L; Gershkovich P; Wasan KM; Mager DE
    Pharm Res; 2014 Jan; 31(1):35-45. PubMed ID: 23793994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.
    Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
    Antimicrob Agents Chemother; 2002 Mar; 46(3):828-33. PubMed ID: 11850268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the pharmacokinetic profiles of two different amphotericin B formulations in healthy dogs.
    Bingöl B; Bakirel T
    J Vet Pharmacol Ther; 2018 Feb; 41(1):e16-e21. PubMed ID: 28815733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.
    Walsh TJ; Goodman JL; Pappas P; Bekersky I; Buell DN; Roden M; Barrett J; Anaissie EJ
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3487-96. PubMed ID: 11709329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs.
    Fielding RM; Singer AW; Wang LH; Babbar S; Guo LS
    Antimicrob Agents Chemother; 1992 Feb; 36(2):299-307. PubMed ID: 1605595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.
    Boswell GW; Bekersky I; Buell D; Hiles R; Walsh TJ
    Antimicrob Agents Chemother; 1998 Feb; 42(2):263-8. PubMed ID: 9527770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.
    Heinemann V; Bosse D; Jehn U; Kähny B; Wachholz K; Debus A; Scholz P; Kolb HJ; Wilmanns W
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1275-80. PubMed ID: 9174183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.
    Walsh TJ; Yeldandi V; McEvoy M; Gonzalez C; Chanock S; Freifeld A; Seibel NI; Whitcomb PO; Jarosinski P; Boswell G; Bekersky I; Alak A; Buell D; Barret J; Wilson W
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2391-8. PubMed ID: 9736569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.
    van Etten EW; ten Kate MT; Stearne LE; Bakker-Woudenberg IA
    Antimicrob Agents Chemother; 1995 Sep; 39(9):1954-8. PubMed ID: 8540697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AmBisome (liposomal amphotericin B): a comparative review.
    Boswell GW; Buell D; Bekersky I
    J Clin Pharmacol; 1998 Jul; 38(7):583-92. PubMed ID: 9702842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.
    Olson JA; Adler-Moore JP; Jensen GM; Schwartz J; Dignani MC; Proffitt RT
    Antimicrob Agents Chemother; 2008 Jan; 52(1):259-68. PubMed ID: 17967910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.
    Lee JW; Amantea MA; Francis PA; Navarro EE; Bacher J; Pizzo PA; Walsh TJ
    Antimicrob Agents Chemother; 1994 Apr; 38(4):713-8. PubMed ID: 8031034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.
    Serrano DR; Hernández L; Fleire L; González-Alvarez I; Montoya A; Ballesteros MP; Dea-Ayuela MA; Miró G; Bolás-Fernández F; Torrado JJ
    Int J Pharm; 2013 Apr; 447(1-2):38-46. PubMed ID: 23438978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
    Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.